Dovepress Table 1 (Continued) Patent number wO/2010/104721 wO/2010/104646 wO/2010/099054 wO/2010/096677 Assignee and country eli Lilly (US) Scott and white Memorial Hospital (US) Merck Sharpe and Dohme (US) invasc Therapeutics (US) wO/2010/095462 Kowa (JP) wO/2010/092811 Nihon University (JP) wO/2010/088279 Cardiomems (US) wO/2010/084231 wO/2010/082367 wO/2010/080183 Fundació institut de Recerca de L’Hospital Universitari Vall d’Hebron (eS) Kikkoman (JP) University of Columbia (US) wO/2010/078624 Vegenics (AU) Subject 5-((E)-(3-fluorodibenzo[b,e]oxepin- 11l(6H)-ylidene)methyl)-l-((7R,8aR)- hexahydro-1 H-pyrrolo [2,1-c][1,4] oxazin-7-yl)-1 H-benzo[d]imidazol- 2(3H)-one, a mineralocorticoid receptor antagonist for kidney disease, hypertension, and heart failure Simultaneous measurement of marinobufagenin and angiotensinogen in urine to differentiate volume extension and vasoconstrictive forms of hypertension Soluble guanylate cyclase activators for endothelial dysfunction, atherosclerosis hypertension, and heart disease Dinitroso-derivatives of dihydrolipoic acid for hypertension, myocardial infarction, stroke, atherosclerosis ect. 3-(5-Akoxypyrimidine-2-yl) pyrimidine- 4(3H)-one dual angiotensin ii receptor antagonist and PPARgamma agonist, for hypertension and metabolic syndrome Biphenylcarboxamide compound for hypertension wearable wireless blood pressure monitoring system with implanted sensor Kidney androgen-regulated protein (KAP) gene expression in renal tissue, for models to evaluate antihypertensive compounds Orally bioavailable angiotensin- converting enzyme (ACe)-inhibiting di- and tripeptides Vasodilatory and anti-inflammatory soluble epoxide hydrolase inhibitors to treat hypertension Vascular endothelial growth factor (VeGF) C and D products for hypertension Patents and companion papers in vascular risk management Published September 16, 2010 None Companion paper September 16, 2010 None September 2, 2010 None August 26, 2010 August 26, 2010 August 19, 2010 August 5, 2010 July 29, 2010 July 22, 2010 July 15, 2010 July 15, 2010 None None None None Circulation. 2009;119(14):1908–1917 J Agric Food Chem. 2010;58(2):821–827 Bioorg Med Chem Lett. 2009;19(8):2354–2359 Nat Med. 2009;15(5):545–552 patenting during the following two decades.6 An analysis of the patenting and publishing data of 395 academic inventors from five major universities in Taiwan from 2002 to 2006 suggested that patenting might increase the number and quality of papers published by these inventors.7 Although the absolute numbers are too low for actual statistics, the available data suggest that corporate inventors are less likely to publish their patented findings in scientific journals than nonprofit inventors. This was expected, since peer-review publishing is firmly rooted in academic culture while the standing of corporate scientists in the life sciences, or their companies, is not usually measured by such criteria. Patents are deemed far more important in this environment. If a 1987 analysis of 17 US pharmaceutical companies has demonstrated their patent data to represent an excellent indicator of overall corporate technological strength,8 there is little reason to assume that this situation has changed fundamentally. In addition, most patents that claim incre- mental improvements over the prior art (eg, a new orally disintegrating tablet formulation for a particular compound, or a variation in the design of a vascular repair device) would not meet the criteria of “novelty” and “non-obviousness” Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com Dovepress 269